Related Experiment Video
Updated: Apr 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Thrombus formation in left atrium on dabigatran therapy
Priyank Shah1, Priyam Mithawala2, Donna Konlian1
1St. Joseph's Regional Medical Center, 703 Main Street, Paterson, NJ 07503, USA.
Insights
Dabigatran, a direct thrombin inhibitor, failed to prevent left atrial thrombus formation and embolic strokes in a patient with atrial fibrillation. This rare case highlights potential mechanisms of dabigatran failure in specific clinical scenarios.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dabigatran is a direct thrombin inhibitor used for stroke prevention in nonvalvular atrial fibrillation.
- It has shown efficacy in resolving left atrial thrombus.
- Left atrial thrombus formation during dabigatran therapy is rare.
Purpose of the Study:
- To report a rare case of left atrial thrombus formation and multiple embolic strokes in a patient treated with dabigatran.
- To explore potential mechanisms underlying dabigatran failure in this context.
Main Methods:
- Case report of a patient with chronic atrial fibrillation on dabigatran 150 mg twice daily.
- Clinical presentation with multiple embolic strokes and confirmed left atrial thrombus.
Main Results:
- The patient developed a left atrial thrombus despite therapeutic dabigatran dosing.
- Multiple embolic strokes occurred, indicating treatment failure.
- This represents one of only four reported cases globally.
Conclusions:
- Dabigatran therapy can fail to prevent left atrial thrombus and thromboembolism in some patients.
- Potential mechanisms include compensatory coagulation factor increases, incomplete thrombin inhibition, and lack of routine monitoring for adherence.
- Further research into monitoring and alternative anticoagulation strategies may be warranted.
Abstract:
Dabigatran is a direct thrombin inhibitor, approved in the United States for stroke prevention in nonvalvular atrial fibrillation and prevention and treatment of thromboembolism. It has been also used in patients with documented left atrial thrombus, where treatment with dabigatran effectively led to thrombus resolution. We present a rare case of left atrial thrombus formation in a patient with chronic atrial fibrillation being treated with dabigatran 150 mg twice a day. The patient presented with multiple embolic strokes. There are only three such cases reported in the literature till date, all of whom had thrombus in the left atrium. The possible mechanisms of dabigatran failure include compensatory increase in upstream coagulation factors due to single level downstream blockade of thrombin, lack of inhibition of all available thrombin, and lack of monitoring measures that can be implemented in common clinical laboratories that lead to failure to assess adherence, which in turn can lead to dabigatran failure.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Clot Retraction and Fibrinolysis

